Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease

Toth, P. P., Schwartz, G. G., Nicholls, S. J., Khan, A., Szarek, M., Ginsberg, H. N., Johansson, J. O., Kalantar-Zadeh, K., Kulikowski, E., Lebioda, K., Wong, N. C. W., Sweeney, M., & Ray, K. K. (2022). Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease. American Journal of Preventive Cardiology, 11, 100372. https://doi.org/10.1016/j.ajpc.2022.100372
Authors:
Peter P Toth
Gregory G Schwartz
Stephen J Nicholls
Aziz Khan
Michael Szarek
Henry N Ginsberg
Jan O Johansson
Kamyar Kalantar-Zadeh
Ewelina Kulikowski
Ken Lebioda
Norman C W Wong
Michael Sweeney
Kausik K Ray
Affiliated Authors:
Henry N Ginsberg
Columbia Affiliation:
Author Keywords:
apabetalone
cardiovascular events
fibrosis
nonalcoholic fatty liver disease
acs, acute coronary syndrome
alp, alkaline phosphatase
alt, alanine aminotransferase
apr, acute phase reactant
ast, aspartate aminotransferase
apoai, aproprotein-ai
bd, bromodoamin
bet, bromodomain and extraterminal proteinfamily
bmi, body mass index
cv, cardiovascular
cvd, cardiovascular disease
fs, fibrosis score
hdl-c, high density lipoprotein cholesterol
hhf, hospitalization for heart failure
hr, hazard ratio
mace, major acute coronary event
nafld, nonalcoholic fatty liver disease
t2dm, type 2 diabetes mellitus
elink
Publication Type:
Article
Unique ID:
10.1016/j.ajpc.2022.100372
PMID:
36039183
DOI:
10.1016/j.ajpc.2022.100372
Journal:
American Journal of Preventive Cardiology
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record
View Scopus Record
View Web of Science Record

Record Created: